Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-986249 + nivolumab
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BMS-986249 + nivolumab is a combination of an engineered probody (BMS-986249) and a monoclonal antibody checkpoint inhibitor (nivolumab) for the treatment of advanced solid tumors, including metastatic melanoma. BMS-986249 is a peptide-masked version of ipilimumab (Yervoy) that targets CTLA-4 but only becomes active in the tumor microenvironment by protease-mediated cleavage, aiming to reduce systemic toxicity while retaining anti-tumor efficacy. Nivolumab (Opdivo) is a monoclonal antibody that targets the programmed death-1 (PD-1) receptor, preventing cancer cells from evading immune detection. Together, these two immune checkpoint inhibitors are designed to enhance T cell activation and anti-tumor immune responses while minimizing systemic side effects. The combination is being developed by Bristol Myers Squibb and CytomX Therapeutics and is in advanced clinical trials for metastatic melanoma and other cancers[1][2][3][4][5][6][7].
- Other names
- anti-CTLA-4 probody + anti–PD-1
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on BMS-986249 + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMS-986249 + nivolumab.